Home » Galapagos, GSK Successfully Conclude Phase IIa Study of Skin Disease Drug
Galapagos, GSK Successfully Conclude Phase IIa Study of Skin Disease Drug
Belgian biotech group Galapagos NV said it has successfully concluded the Phase IIa study of a skin disease drug it is developing with Britain’s GlaxoSmithKline.
Reuters
Reuters
Upcoming Events
-
07May
-
14May
-
30May